September 18, 2023 (Earnings Report) Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Darden
Symbol: DRI
Recent Price: $150.06
Average Analyst Price Target: $171.60 (15.78%)
Market Cap: $18.14B
Last Year's EPS: 2.34
Consensus EPS Forecast: 2.54
Expected Earnings Date: 2023-06-22
Recent Analyst Action: Sara Senatore, analyst at Bank of America Securities, reiterates coverage on Darden (DRI) in the Consumer Cyclical sector with a Buy rating and a price target of $187 (2 days ago).
TipRanks.com also reports that Darden currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $171.60 . The target pricing ranges from a high forecast of $187 down to a low forecast of $160. Darden (DRI)’s last closing price was $150.06 which would put the average price target at 15.78% upside.Here are 3rd party ratings for DRI:
Recent Analyst Action: Seth Weber, analyst at Wells Fargo, reiterates coverage on Factset Research (FDS) in the Financial sector with a Hold rating and a price target of $435 (1 week ago).
TipRanks.com also reports that Factset Research currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $453.80 . The target pricing ranges from a high forecast of $480 down to a low forecast of $419. Factset Research (FDS)’s last closing price was $427.67 which would put the average price target at 0.57% upside.Here are 3rd party ratings for FDS:
Recent Analyst Action: Randal Konik, analyst at Jefferies, reiterates coverage on Manchester United (MANU) in the Consumer Cyclical sector with a Buy rating and a price target of $26 (2 months ago).
TipRanks.com also reports that Manchester United currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $25.50 . The target pricing ranges from a high forecast of $26 down to a low forecast of $25. Manchester United (MANU)’s last closing price was $19.09 which would put the average price target at 33.58% upside.Here are 3rd party ratings for MANU:
Recent Analyst Action: Edward White, analyst at H.C. Wainwright, reiterates coverage on Valneva (VALN) in the Healthcare sector with a Buy rating and a price target of $22 (1 week ago).
TipRanks.com also reports that Valneva currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.33 . The target pricing ranges from a high forecast of $22 down to a low forecast of $16. Valneva (VALN)’s last closing price was $14.17 which would put the average price target at 55.26% upside.Here are 3rd party ratings for VALN:
Recent Analyst Action: James Hardiman, analyst at Citi, reiterates coverage on Thor Industries (THO) in the Industrials sector with a Hold rating and a price target of $107 (2 weeks ago).
TipRanks.com also reports that Thor Industries currently has 3 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $100.33 . The target pricing ranges from a high forecast of $84 down to a low forecast of $107. Thor Industries (THO)’s last closing price was $95.30 which would put the average price target at 12.28% upside.Here are 3rd party ratings for THO:
Recent Analyst Action: Jason McCarthy, analyst at Maxim Group, reiterates coverage on Kintara Therapeutics (KTRA) in the Healthcare sector with a Buy rating and a price target of $14 (2 months ago).
TipRanks.com also reports that Kintara Therapeutics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $14.00 . The target pricing ranges from a high forecast of $14 down to a low forecast of $14. Kintara Therapeutics (KTRA)’s last closing price was $4.16 which would put the average price target at 236.54% upside.Here are 3rd party ratings for KTRA:
To Your Financial Future,
The Editor, WallStreetSectors.com